DAX24.423 +1,3%Est505.646 +1,2%MSCI World4.322 ±-0,0%Top 10 Crypto16,80 +3,0%Nas22.808 +0,2%Bitcoin102.615 +1,7%Euro1,1711 -0,2%Öl64,08 -2,1%Gold3.838 -0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
DroneShield A2DMAA Rheinmetall 703000 NVIDIA 918422 RENK RENK73 Siemens Energy ENER6Y Tesla A1CX3T Novo Nordisk A3EU6F Bayer BAY001 Plug Power A1JA81 Alibaba A117ME Lufthansa 823212 HENSOLDT HAG000 BASF BASF11 Deutsche Telekom 555750 thyssenkrupp 750000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX letztlich kräftig im Plus -- Tesla meldet Rekord-Auslieferungen in Q3 -- BioNTech, DroneShield, Siemens Energy, Novo Nordisk, BYD, Rüstungsaktien, Wolfspeed, Stellantis im Fokus
Top News
HENSOLDT-Aktie profitiert von erweiterter Radarproduktion mit neuem Standort - auch RENK und Rheinmetall stark HENSOLDT-Aktie profitiert von erweiterter Radarproduktion mit neuem Standort - auch RENK und Rheinmetall stark
Novo Nordisk-Aktie legt zu: US-Deal mit Pfizer und Kaufempfehlung im Blick Novo Nordisk-Aktie legt zu: US-Deal mit Pfizer und Kaufempfehlung im Blick
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

YS Biopharma Company Aktie

Kaufen
Verkaufen
Handle Aktien, ETFs, Derivate & Kryptos ohne Ordergebühren (zzgl. Spreads) beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 11/2024)
Smartphone
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA3D4XP

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINKYG9845F1090

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolLSB

YS Biopharma Company Aktien News

DatumMeistgelesen
PR NewswireLakeShore Biopharma Announces Receipt of Delisting Determination Letter from Nasdaq
PR NewswireLakeShore Biopharma Announces Appointment of Independent Financial Advisor and Legal Counsel to the Special Committee
PR NewswireLakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
PR NewswireLakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
PR NewswireLakeShore Biopharma Announces Fiscal Year 2025 Financial Results
PR NewswireLakeShore Biopharma Announces US$15 Million Private Placement Financing
PR NewswireLakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell)
PR NewswireLakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
PR NewswireLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR NewswireLakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR NewswireLakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
PR NewswireLakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
PR NewswireLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
PR NewswireLakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
PR NewswireLakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
PR NewswireLakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
PR NewswireLakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
PR NewswireLakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
PR NewswireLakeShore Biopharma Announces Leadership Transitions
PR NewswireLakeShore Biopharma Announces Leadership Transitions
PR NewswireLakeShore Biopharma Announces Financial Results for Fiscal Year 2024
PR NewswireLakeShore Biopharma Announces Financial Results for Fiscal Year 2024
PR NewswireLakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
PR NewswireLakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
PR NewswireYS Biopharma Announces Name Change to LakeShore Biopharma
PR NewswireYS Biopharma Announces Name Change to LakeShore Biopharma
PR NewswireYS Biopharma Announces Results of Extraordinary General Meeting
PR NewswireYS Biopharma Announces Results of Extraordinary General Meeting
PR NewswireYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
PR NewswireYS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer
PR NewswireYS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
PR NewswireYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
PR NewswireYS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024
PR NewswireYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
PR NewswireYS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine
PR NewswireYS Biopharma to Report First Nine Months of Fiscal Year 2024 Financial Results on April 19, 2024
PR NewswireYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
PR NewswireYS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine
PR NewswireYS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility
PR NewswireYS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility

YS Biopharma Company News

YS Biopharma Company News: auf dieser Seite finden Sie alle YS Biopharma Company News und Nachrichten zur YS Biopharma Company Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch YS Biopharma Company News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um YS Biopharma Company News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.